AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12667322
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (10 ml at 4 ml/min) as control
Trial: 9707191
Drug: 100 mL
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL HS‐HES
Trial: 9707191
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g mannitol
Trial: 7661873
Drug: Pravastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (40 mg/g)
Trial: 7661873
Drug: Gemfibrozil (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil (1200 mg/day)
Trial: 7661873
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Pravastatin and Gemfibrozil (40 + 1200 mg/day)
Trial: 31704740
Drug: Rivaroxaban 10
RxNorm normalized name: rivaroxaban 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 10 mg daily plus vitamin K2 2000 µg thrice weekly
Trial: 31704740
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K antagonists (VKAs) with target INR 2‐3
Trial: 23812272
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion of 2 mg/kgBW/h
Trial: 20151997
Drug: Doubling atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doubling atorvastatin to 80 mg
Trial: 16491133
Drug: Reboxetine plus
RxNorm normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine plus 400 mg celecoxib for 6 weeks
Trial: 11007240
Drug: Immunosuppressive drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive drug therapy (glucocorticoids, cyclosporin, FK 506)
Trial: 1523353
Drug: Acarbose 100
RxNorm normalized name: acarbose 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose 100 mg tid during 12 weeks
Trial: 6498567
Drug: Group III:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group III: Same as Group I with addition of fentanyl (2 micrograms X kg‐1) before skin incision and 1/8 of the initial dose every 15 minutes during surgery
Trial: 6498567
Drug: Group IV:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group IV: Same as Group I with additional infusion of lidocaine (30 micrograms X kg‐1 X min‐1)
Trial: 6498567
Drug: Group V:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group V: 0.65 MAC of nitrous oxide and fentanyl (7.5 micrograms X kg‐1) before skin incision with 1/8 of the initial dose every 15 minutes during the operation
Trial: 6498567
Drug: Group VI:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group VI: 0.65 MAC of nitrous oxide and fentanyl (15 micrograms X kg‐1) before skin incision with 1/8 of the initial dose every 15 minutes during the operation
Trial: 7561435
Drug: Cefoxitin prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin prophylaxis (2 g intravenously, n = 25)
Trial: 31412242
Drug: Nicotinamide riboside
RxNorm normalized name: Nicotinamide riboside
DrugBank: Nicotinamide riboside (DB14933)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinamide riboside (NR) 1 g per day for 21 days
Trial: 28978802
Drug: Yellow fever
RxNorm normalized name: yellow fever live
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yellow fever live‐attenuated vaccine (YFLAV)
Trial: 23761087
Drug: DEX implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX implant 0.70 mg
Trial: 20168099
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 2 x 5 mg (5 mg intravenously at randomization and at month 12)
Trial: 20168099
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 1 x 5 mg (5 mg intravenously at randomization and placebo at month 12)
Trial: 17935572
Drug: Daily infant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily infant probiotic supplement for the first 6 months of life
Trial: 15453623
Drug: Topical benzydamine
RxNorm normalized name: benzydamine Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical benzydamine hydrochloride 3% cream
Trial: 9389780
Drug: Oestradiol gel
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oestradiol gel (1.0 mg of oestradiol daily, Divigel/Sandrena)
Trial: 9389780
Drug: Oestradiol delivering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestradiol delivering patch (50 micrograms oestradiol/24 h, Estraderm TTS)
Trial: 29618017
Drug: Monthly practice
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly practice for 6 months
Trial: 26365335
Drug: S05985 (perindopril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S05985 (perindopril 5 mg and amlodipine 5 mg)
Trial: 26365335
Drug: Perindopril tert‐butylamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril tert‐butylamine 4 mg
Trial: 24216317
Drug: Atorvastatin preloading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin preloading (80 mg 12 h and 40 mg 2 h pre-PCI)
Trial: 24216317
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (atorvastatin 40 mg/day)
Trial: 24216317
Drug: Atorvastatin preloading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin preloading
Trial: 16618403
Drug: 48 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 48 weeks of peginterferon-alfa-2a (180 microg/wk) plus ribavirin (800 mg/day)
Trial: 16618403
Drug: 72 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 72 weeks of peginterferon-alfa-2a (180 microg/wk) plus ribavirin (800 mg/day)
Trial: 16618403
Drug: 72 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 72 weeks of treatment for patients HCV-RNA positive at week 12
Trial: 14563580
Drug: Activated protein
RxNorm normalized name: Activated protein C
DrugBank: Drotrecogin alfa (DB00055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated protein C (APC) at 0.06 mg/kg per day
Trial: 14563580
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin at 100 to 400 U/kg per day
Trial: 11459333
Drug: Olanzapine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (5 mg/day titrated to a maximum of 20 mg/day)
Trial: 9205772
Drug: Cordaflex 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cordaflex 20 mg retard filmtablet
Trial: 3677542
Drug: Lamotrigine 120
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine 120 mg
Trial: 16476149
Drug: T allele
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T allele of G protein beta3 (GNbeta3)
Trial: 9197351
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) treatment group (15 mg/kg/day)
Trial: 31160805
Drug: Periprostatic nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periprostatic nerve block combined with subcutaneous perineal anaesthesia and intrarectal lidocaine gel
Trial: 28062082
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment (Control group, n=30)
Trial: 26604652
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (patient controlled intravenous analgesia)
Trial: 21600087
Drug: Antofloxacin hydrochloride
RxNorm normalized name: danofloxacin
DrugBank: Danofloxacin (DB11393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antofloxacin hydrochloride tablet
Trial: 21600087
Drug: Levofloxacin tablet
RxNorm normalized name: Levofloxacin Tablets
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin tablet
Trial: 12868802
Drug: Docetaxel 100
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 100 mg/m2 every 3 weeks for four cycles
Trial: 10470596
Drug: Amtolmetin guacyl
RxNorm normalized name: Amtolmetin guacil
DrugBank: Amtolmetin guacil (DB16088)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amtolmetin guacyl 600 mg bid
Trial: 7041522
Drug: 1,25(OH)2D3 (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,25(OH)2D3 (0.5 micrograms daily)
Trial: 19660001
Drug: Branded amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Branded amoxicillin
Trial: 17551492
Drug: Post-treatment groups
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment groups (adjuvant therapy)
Trial: 11472320
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with ranitidine (300 mg), amoxicillin (1000 mg), and clarithromycin (500 mg) for 7 days
Trial: 9493257
Drug: Anti-hypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-hypertensive treatment A
Trial: 9493257
Drug: Anti-hypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-hypertensive treatment B
Trial: 7931701
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (0.65 mg)
Trial: 7931701
Drug: Vitamin B‐12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B‐12 (0.4 mg)
Trial: 7931701
Drug: Vitamin B‐6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B‐6 (10 mg)
Trial: 7931701
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of folic acid, vitamin B‐12, and vitamin B‐6
Trial: 3348136
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) oral spray
Trial: 21280077
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses (20 mg and 40 mg)
Trial: 19878986
Drug: Metformin (850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (850 mg twice daily as tolerated)
Trial: 16861405
Drug: RA plus
RxNorm normalized name: Mokura Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RA plus clonidine 1 microg/kg as the initial loading dose followed by 1 microg.kg(‐1).h(‐1)
Trial: 12611558
Drug: Oral fenugreek
RxNorm normalized name: FENUGREEK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fenugreek seed powder
Trial: 28968167
Drug: Gefitinib 250
RxNorm normalized name: gefitinib 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib 250 mg plus cisplatin 75 mg/m2 plus pemetrexed 500 mg/m2
Trial: 28968167
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus cisplatin 75 mg/m2 plus pemetrexed 500 mg/m2
Trial: 28968167
Drug: Gefitinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib plus chemotherapy in T790M mutation-positive patients
Trial: 28968167
Drug: Gefitinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib plus chemotherapy in T790M mutation-negative patients
Trial: 28968167
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus chemotherapy in T790M mutation-negative patients
Trial: 23408495
Drug: Intravenous carbamazepine
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous carbamazepine (CBZ) 100 mg dose as partial replacement of morning dose
Trial: 23408495
Drug: Intravenous carbamazepine
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous carbamazepine (CBZ) 100 mg dose
Trial: 19394661
Drug: glyburide 10
RxNorm normalized name: Glyburide
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glyburide 10 mg/d
Trial: 15658652
Drug: Shenqi Fuzheng
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenqi Fuzheng injection (SFI) plus conventional therapy (mainly glucocorticoids)
Trial: 15658652
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (mainly glucocorticoids)
Trial: 30623096
Drug: bococizumab 150,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bococizumab 150, 300, or 450 mg co‐mixed with rHuPH20
Trial: 30623096
Drug: bococizumab 300
RxNorm normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: bococizumab 300 mg + rHuPH20
Trial: 30623096
Drug: bococizumab 300
RxNorm normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: bococizumab 300 mg alone
Trial: 20463587
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen (clear liquid diet, 4 L of PEG, and 1 or 2 NaP boosters)
Trial: 20463587
Drug: Modified regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified regimen (1 or 2 PEG boosters, 4 senna tablets, and a low-residue diet)
Trial: 19356075
Drug: Cyclosporine (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (single oral dose)
Trial: 19356075
Drug: Cyclosporine PBMC
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine PBMC pharmacokinetics
Trial: 12552363
Drug: Hydrocodone bitartrate
RxNorm normalized name: Hydrocodone Bitartrate
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Hydrocodone bitartrate (7.5 mg) plus ibuprofen (200 mg)
Trial: 9365149
Drug: Omeprazole, 20
RxNorm normalized name: Omeprazole, 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole, 20 mg by mouth twice a day for eight weeks
Trial: 31037562
Drug: Everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 10 mg daily for 8 weeks
Trial: 31037562
Drug: Everolimus 5
RxNorm normalized name: everolimus 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 5 mg daily for 8 weeks
Trial: 21896132
Drug: 10% glycolic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% glycolic acid containing oil-in-water emulsion applied once daily in the evening for 90 days
Trial: 19219442
Drug: Local injection
RxNorm normalized name: Sclerosing agents for local injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local injection of a steroid (1 mL triamcinolone) combined with local anaesthetic (1 mL lidocaine) in group A
Trial: 19219442
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of local anaesthetic (1 mL lidocaine) combined with peppering technique in group B
Trial: 19219442
Drug: Local injection
RxNorm normalized name: Sclerosing agents for local injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local injection of a steroid (1 mL triamcinolone) combined with local anaesthetic (1 mL lidocaine) and peppering technique in group C
Trial: 14523786
Drug: Subcutaneously administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously administered recombinant interleukin-2 (rIL-2)
Trial: 14523786
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy without rIL-2 (Control)
Trial: 9890319
Drug: Intermittent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent treatment with glycopeptide (vancomycin or teicoplanin) and ceftazidime
Trial: 9890319
Drug: Continuous treatment
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous treatment with glycopeptide (vancomycin or teicoplanin) and ceftazidime
Trial: 9890319
Drug: Intermittent ceftazidime
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent ceftazidime treatment
Trial: 9890319
Drug: Continuous ceftazidime
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous ceftazidime treatment
Trial: 9890319
Drug: Intermittent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent treatment with glycopeptide and ceftazidime
Trial: 9890319
Drug: Continuous treatment
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous treatment with glycopeptide and ceftazidime
Trial: 9890319
Drug: Intermittent and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent and continuous treatment
Trial: 7752906
Drug: Gemfibrozil 1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil 1,200 mg daily for 12 weeks
Trial: 21858548
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (5 mg elemental Zn per day)
Trial: 18269665
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) applied to one side of the operation area for 7 days
Trial: 1626795
Drug: Nasal administration
RxNorm normalized name: Novel Influenza-H1N1-09, live virus for nasal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal administration of beclamethasone dipropionate (400 micrograms total, 100 micrograms four times per day)
Trial: 1626795
Drug: Bronchial administration
RxNorm normalized name: Bronchitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bronchial administration of beclamethasone dipropionate (400 micrograms total, 100 micrograms four times per day)
Trial: 1626795
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered into the nose when B was administered into the bronchi and vice versa)
Trial: 29697876
Drug: Osimertinib (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib (80 mg/d)
Trial: 29697876
Drug: Platinum-based therapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-based therapy plus pemetrexed (500 mg/m2)
Trial: 29697876
Drug: Platinum-based therapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-based therapy plus pemetrexed
Trial: 27492510
Drug: Ang‐2 levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ang‐2 levels in survivors during treatment
Trial: 20577923
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition (TPN) for 10 days perioperation (7 days preoperatively and 3 days postoperatively)
Trial: 20577923
Drug: Non total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non total parenteral nutrition (NTPN)
Trial: 3593896
Drug: Quinidine sulfate
RxNorm normalized name: Quinidine Sulfate
DrugBank: Quinidine (DB00908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinidine sulfate controlled release (600 mg day-1 for 4 days)
Trial: 3593896
Drug: Quinidine gluconate
RxNorm normalized name: Quinidine Gluconate
DrugBank: Quinidine (DB00908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinidine gluconate controlled release (600 mg day-1 for 4 days)
Trial: 3593896
Drug: Quinidine sulfate
RxNorm normalized name: Quinidine Sulfate
DrugBank: Quinidine (DB00908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinidine sulfate extended-release (300 mg q12h)
Trial: 3593896
Drug: Quinidine sulfate
RxNorm normalized name: Quinidine Sulfate
DrugBank: Quinidine (DB00908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinidine sulfate in solution (150 mg q6h)
Trial: 3593896
Drug: Quinidine gluconate
RxNorm normalized name: Quinidine Gluconate
DrugBank: Quinidine (DB00908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinidine gluconate controlled-release (q12h)
Trial: 27443598
Drug: Sarcosine (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarcosine (0.03 g/kg/day)
Trial: 25585502
Drug: Intraperitoneal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal bupivacaine 0.25% + 1 μg/kg Dex (GIII)
Trial: 19038771
Drug: Pregabalin, 300
RxNorm normalized name: Pregabalin, 300 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin, 300 mg single oral dose
Trial: 19038771
Drug: Morphine, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine, 10 mg IV
Trial: 19038771
Drug: Diphenhydramine, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine, 50 mg oral dose
Trial: 16803605
Drug: 7-day ranitidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day ranitidine bismuth citrate-based triple therapy (ranitidine bismuth citrate + amoxicillin + clarithromycin)